Kelliop Inc., a leading innovator in decentralized molecular diagnostics, is pleased to announce its upcoming participation in the
ADLM 2025 Annual Meeting & Clinical Lab Expo, to be held in
Chicago, IL from July 27–31, 2025.
At the event, Kelliop will showcase RapidSeq126™, the world’s highest-throughput molecular point-of-care testing (POCT) platform. Designed for real-time, multiplexed genetic testing, RapidSeq126™ integrates proprietary microfluidics, thermal management, and photonics into a compact, self-developed system capable of analyzing up to 144 molecular targets in under 60 minutes.
Kelliop's technology supports a wide range of clinical applications, including newborn hearing screening, pharmacogenomics, and environmental pathogen detection, with a unique closed-loop ecosystem of instruments and consumables developed entirely in-house.
“We look forward to meeting clinicians, lab directors, and industry partners at ADLM to explore collaboration opportunities,” said Frank Chen, Co-Founder of Kelliop. “Our goal is to enable just-in-time diagnostics at the point of care, improving speed and accessibility without compromising performance.”
Kelliop will be exhibiting at Booth #4538, and invites attendees to experience live demonstrations and discuss ODM, co-development, and global distribution partnerships.
About Kelliop
Kelliop Inc. is a precision medicine company based in Fresno, California, developing next-generation molecular POCT solutions. Its flagship platform RapidSeq126™ delivers ultra-fast, high-throughput, multiplexed diagnostics through proprietary microfluidic innovation, supporting decentralized testing across clinical and industrial domains.